-
公开(公告)号：WO2007124299A8
公开(公告)日：2008-11-06
申请号：PCT/US2007066757
申请日：2007-04-17
Applicant: NOVARTIS AG , XOMA TECHNOLOGY LTD , LU XIAOFENG , CHEN BAO-LU , ARAYA KIDISTI , OKHAMAFE AUGUSTUS
Inventor： LU XIAOFENG , CHEN BAO-LU , ARAYA KIDISTI , OKHAMAFE AUGUSTUS
IPC: C07K16/28
CPC classification number: C07K16/2878 , C07K2317/24 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/94
Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti- CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody -containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
Abstract translation: 提供了包含作为治疗或预防活性组分的拮抗性抗CD40抗体的稳定液体药物组合物以及可用于其制备的方法。 这些组合物包含拮抗性抗-CD40抗体，将组合物的pH保持在约pH5.0与约pH7.0之间的缓冲剂，和足以使液体组合物接近等渗的量的精氨酸-HCl。 本发明的含稳定液体拮抗剂抗-CD40抗体的药物组合物可用于治疗增殖性疾病和具有自身免疫和/或炎症成分的疾病的方法。
-
Patent Agency Ranking
公开(公告)号：WO2007124299A2
公开(公告)日：2007-11-01
申请号：PCT/US2007/066757
申请日：2007-04-17
Applicant: NOVARTIS AG , XOMA TECHNOLOGY LTD. , LU, Xiaofeng , CHEN, Bao-Lu , ARAYA, Kidisti , OKHAMAFE, Augustus
Inventor： LU, Xiaofeng , CHEN, Bao-Lu , ARAYA, Kidisti , OKHAMAFE, Augustus
CPC classification number: C07K16/2878 , C07K2317/24 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/94
Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti- CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody -containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
Abstract translation: 提供了包含拮抗性抗CD40抗体作为治疗或预防活性成分的稳定的液体药物组合物和可用于其制备的方法。 这些组合物包含拮抗性抗-CD40抗体，保持组合物的pH在约pH5.0和约pH7.0之间的缓冲剂和足以使液体组合物接近等渗的精氨酸-HCl的量。 本发明的稳定的液体拮抗剂抗CD40抗体的药物组合物可用于治疗具有自身免疫和/或炎性成分的增殖性疾病和疾病的方法。
-
3.发明申请
公开(公告)号：WO2005044854A3
公开(公告)日：2005-08-11
申请号：PCT/US2004037152
申请日：2004-11-04
Applicant: CHIRON CORP , LONG LI , LUQMAN MOHAMMAD , YABANNAVAR ASHA , ZAROR ISABEL , CHEN BAO-LU , LU XIAOFENG , LEE SANG HOON , HURST DEBORAH
Inventor： LONG LI , LUQMAN MOHAMMAD , YABANNAVAR ASHA , ZAROR ISABEL , CHEN BAO-LU , LU XIAOFENG , LEE SANG HOON , HURST DEBORAH
CPC classification number: C07K16/2878 , A61K38/2013 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40expressing cells, such as B cells.
Abstract translation: 提供了用于治疗由表达CD40的细胞上的CD40信号传导介导的疾病的治疗方法。 该方法包括向有需要的患者施用治疗有效量的拮抗性抗-CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗剂活性有益地抑制人CD40表达细胞如B细胞的增殖和/或分化。
-
公开(公告)号：WO2019204963A1
公开(公告)日：2019-10-31
申请号：PCT/CN2018/084069
申请日：2018-04-23
Applicant: SIEMENS AKTIENGESELLSCHAFT , HAINAN JINPAN SMART TECHNOLOGY CO., LTD. , NAVARRO, Martin Alsina , MORENO, Andre Luiz , WANG, Yaoqiang , ZHANG, Yuqian , LU, Xiaofeng
Inventor： NAVARRO, Martin Alsina , MORENO, Andre Luiz , WANG, Yaoqiang , ZHANG, Yuqian , LU, Xiaofeng
IPC: H01F29/02
Abstract: A tap changer assembly of a dry-type transformer. The tap changer assembly includes a first molding including multiple taps, a semi-conductive coating applied to the first molding, a conductive shield provided overtop some of the semi-conductive coating, a grounding member comprising a ring of bosses interconnected by a grounding conductor connected to the conductive shield, a second molding applied over at least a portion of the conductive shield and the grounding conductor, the second molding forming a molded sealing surface, a conductive cover coupled to the ring of bosses; and a sealing member sealing a space between the molded sealing surface and the conductive cover. Dry-type transformers and methods of forming a tap changer assembly of a dry-type transformer are provided, as are numerous other aspects.
-
公开(公告)号：WO2007124299A3
公开(公告)日：2008-01-03
申请号：PCT/US2007066757
申请日：2007-04-17
Applicant: NOVARTIS AG , XOMA TECHNOLOGY LTD , LU XIAOFENG , CHEN BAO-LU , ARAYA KIDISTI , OKHAMAFE AUGUSTUS
Inventor： LU XIAOFENG , CHEN BAO-LU , ARAYA KIDISTI , OKHAMAFE AUGUSTUS
IPC: C07K16/28
CPC classification number: C07K16/2878 , C07K2317/24 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/94
Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti- CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody -containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
Abstract translation: 提供了包含拮抗性抗CD40抗体作为治疗或预防活性成分的稳定的液体药物组合物和可用于其制备的方法。 这些组合物包含拮抗性抗-CD40抗体，保持组合物的pH在约pH5.0和约pH7.0之间的缓冲剂和足以使液体组合物接近等渗的精氨酸-HCl的量。 本发明的稳定的液体拮抗剂抗CD40抗体的药物组合物可用于治疗具有自身免疫和/或炎性成分的增殖性疾病和疾病的方法。
-
6.发明申请ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE 审中-公开ANTAGONIST抗CD40单克隆抗体及其使用方法
公开(公告)号：WO2005044854A2
公开(公告)日：2005-05-19
申请号：PCT/US2004/037152
申请日：2004-11-04
Applicant: CHIRON CORPORATION , LONG, Li , LUQMAN, Mohammad , YABANNAVAR, Asha , ZAROR, Isabel , CHEN, Bao-Lu , LU, Xiaofeng , LEE, Sang, Hoon , HURST, Deborah
Inventor： LONG, Li , LUQMAN, Mohammad , YABANNAVAR, Asha , ZAROR, Isabel , CHEN, Bao-Lu , LU, Xiaofeng , LEE, Sang, Hoon , HURST, Deborah
IPC: C07K16/00
CPC classification number: C07K16/2878 , A61K38/2013 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40expressing cells, such as B cells.
Abstract translation: 提供了通过CD40表达细胞上的CD40信号传导介导的治疗疾病的治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制人CD40表达细胞如B细胞的增殖和/或分化。
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
